Claritev Corporation

NYSE:CTEV

Medical - Healthcare Information Services

Healthcare
$22.30 +1.41%

+$0.42 today

Market cap
$380.77M
Beta
0.77
P/E (TTM)
-1.8
EPS (TTM)
-$17.16
52W Low $11.50High $74.07

Volume 0.31M

Average 0.14M

CTEV EBITDA Margin

EBITDA as a percentage of revenue.

Claritev CorporationNYSE: CTEV

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 47.7%

EBITDA Margin was 47.7% in Q1 FY2026, down 1.2 pp from a year earlier. On a trailing-twelve-month basis it was 52.9%, up 109.3 pp year over year. Over 3 fiscal years it widened by 34.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 47.3% for the fiscal year ending Dec 2026, down from 49.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
47.7%+5.3 pp QoQ
Last fiscal yearDec 2025
49.2%+157.6 pp YoY
LTMMar 2026
52.9%+109.3 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.2 pp+4.3 pp+5.5 pp
1 year+157.6 pp-1.9 pp-159.5 pp
3 years+34.6 pp-10.7 pp-45.3 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
49.2%
Year-over-year change
+157.6pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CTEV compares with its peers on the latest reported figures

  • CTEV's LTM Mar 2026 EBITDA Margin of 52.9% is the highest of the 10 companies compared; the peer median is -6.0%.
  • Its year-over-year change of +109.3 pp is the 2nd highest of 10, against a peer median of -8.4 pp.
  • Over three fiscal years its change of +34.6 pp compares with a peer median of +5.1 pp.
CTEV Competitors Peer median
EBITDA Margin for CTEV and competitors
Company Period LTM level YoY 3-year change
CTEVClaritev CorporationLTM Mar 202652.9% +109.3 pp+34.6 pp
IRMDIRadimed CorporationLTM Mar 202637.4% +3.1 pp+5.1 pp
INMDInMode Ltd.LTM Mar 202627.5% -8.4 pp-14.5 pp
GDRXGoodRx Holdings, Inc.LTM Mar 202622.0% +0.5 pp+14.6 pp
LFMDLifeMD, Inc.LTM Mar 2026-1.9% -3.3 pp+31.6 pp
OPKOPKO Health, Inc.LTM Mar 2026-6.0% -27.8 pp+20.2 pp
AXGNAxoGen, Inc.LTM Sep 2026-8.0% -18.0 pp+17.0 pp
EVHEvolent Health, Inc.LTM Mar 2026-16.7% -18.0 pp-22.5 pp
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026-17.6% -28.7 pp-44.6 pp
DNTHDianthus Therapeutics, Inc.LTM Jun 2026-1550.9% +804.4 pp-7510.8 pp
SANASana Biotechnology, Inc.FY2025— ——
Peer median (excluding CTEV) -6.0%-8.4 pp+5.1 pp

Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.12B1.08B961.52M930.62M965.41M
Cost of Revenue175.29M204.1M235.47M239.4M698.84M
Gross Profit942.31M875.62M726.06M691.22M266.58M
Gross Margin84.3%81.1%75.5%74.3%27.6%
Research & Development00000
Selling, General & Admin151.1M132.14M135.99M160.22M221.52M
Operating Expenses556.19M1.24B564.07M2.08B221.52M
Depreciation & Amortization412.06M415.66M425.79M436.44M448.45M
EBITDA814.99M158.32M651.93M(1.01B)475.44M
EBITDA Margin72.9%14.7%67.8%-108.3%49.2%
Operating Income386.12M(362.73M)161.98M(1.39B)45.06M
Operating Margin34.5%-33.6%16.8%-149.4%4.7%
Interest Income30K3.5M8.23M3.13M1.56M
Interest Expense267.48M303.4M333.21M326.37M400.07M
Other Income / Expenses(250.67M)(198.01M)(269.04M)(380.78M)(418.14M)
Income Before Tax135.45M(560.74M)(107.06M)(1.77B)(373.08M)
Pre-Tax Margin12.1%-51.9%-11.1%-190.3%-38.6%
Income Tax Expense33.37M12.17M(15.36M)(124.88M)(88.8M)
Net Income102.08M(572.91M)(91.7M)(1.65B)(284.28M)
Net Margin9.1%-53.1%-9.5%-176.9%-29.4%
EPS (Basic)6.40(35.87)(5.69)(101.92)(17.30)
EPS (Diluted)6.40(35.87)(5.69)(101.92)(17.30)
Weighted Avg Shares16.28M15.97M16.13M16.15M16.43M
Weighted Avg Shares (Diluted)16.29M15.97M16.13M16.15M16.43M

Claritev Corporation

NYSE:CTEV

Intrinsic Alpha fair value

Locked

Current Price

$22.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.